| Literature DB >> 29315416 |
Fang Fang1, Zili Li1,2, Qian Zhao1, Honggang Li1, Chengliang Xiong1,2.
Abstract
Recently, significant progress has been made in ART for the treatment of male infertility. However, current ART has failed to help infertile patients with non-obstructive azoospermia, unless donor sperm is used. In fact, most couples wish to have their own genetically related child. Human induced pluripotent stem cells (hiPSCs) can be generated from patients' somatic cells and in vitro derivation of functional germ cells from patient-specific iPSCs may provide new therapeutic strategies for infertile couples. The overall developmental dynamics of human primordial germ cells are similar to that in mice, but accumulating evidence suggests that there are crucial differences between human and mouse PGC specification. Unlike mouse iPSCs (miPSCs) in naive state, hiPSCs exhibit a primed pluripotency which possess less potential for the germ cell fate. Based on research in mice, male germ cells at different stages have been derived from hiPSCs with different protocols, including spontaneous differentiation, overexpression of germ cell regulators, addition of cytokines, co-culture with gonadal cells in vitro and xeno-transplantation. The aim of this review is to summarize the current advances in derivation of male germ cells from hiPSCs and raise the perspectives of hiPSCs in medical application for male infertility, as well as in basic research for male germ cell development.Entities:
Keywords: embryonic stem cells; extracellular vesicles; gene editing; germ cell differentiation; induced pluripotent stem cells; male infertility; primordial germ cells; reproductive medicine
Mesh:
Year: 2018 PMID: 29315416 PMCID: PMC5850345 DOI: 10.1093/humrep/dex369
Source DB: PubMed Journal: Hum Reprod ISSN: 0268-1161 Impact factor: 6.918
The in vitro differentiation potential of human iPSCs into male germ cells.
| Authors | Donor cells | Methods | Reporters | Isolation strategy | RNA markers | Protein markers | Results | Genetic and epigenetic analysis | |
|---|---|---|---|---|---|---|---|---|---|
| Dermal fibroblasts | Co-culture with human fetal gonadal cells | SSEA1+/cKIT+/VASA+ and PLAP+/SSEA1+/VASA+ | VASA, PRDM1, DPPA3, and DAZL | cKIT and VASA | PGCLCs | Incomplete imprint erasure | |||
| Fetal- and adult-derived fibroblasts | BMP-induced culture and overexpression of the DAZ gene family | VASA:GFP reporter | VASA:GFP+ | VASA, IFITM1, PELOTA, PRDM1A, GCNF, STELLAR, and DMC1 | VASA, DAZL, SCP3, CENP-A and Acrosin | Meiotic cells and haploid cell | DNA content analysis, and FISH | ||
| Keratinocytes and cord blood | 3-step methods (RA, FRSK, LIF, R115866) | CD9+/CD49f++/CD90−/SSEA-4− | VASA and Stra8 | VASA, SCP3, γ-H2AX and Acrosin | Haploid gamete-like cells | DNA content analysis, FISH, and incomplete imprinting re-establishment | |||
| Foreskin fibroblast | Standardized mouse SSC culture conditions | Isolation for haploid cells | VASA, DAZL, CXCR4, PIWIL1, and PLZF | VASA, DAZL, UTF1, CDH1, RET, GFRα1, PIWIL1, HIWI, SCP3, TP1, protamine 1 and Acrosin | Haploid spermatogenic cells | DNA content analysis, FISH, and similar parent imprints | |||
| Fetal- and adult-derived fibroblasts | Overexpression of VASA and/or DAZL and spontaneous differentiation | VASA:GFP reporter | VASA:GFP+ | VASA, IFITM1, DAZL, PRDM1A, GCNF, GDF3, cKIT, PELOTA, SCP3, MLH1, DMC1, GDF9, and ZP4 | VASA, CENP-A, SCP3 and Acrosin | Meiotic cells | DNA content analysis, FISH, and recapitulation of epigenetic reprogramming at the H19 locus | ||
| Dermal fibroblasts | Ectopic expression of VASA | BMP4 treatment | NANOS3, VASA, and DPPA3 | VASA, DAZ, DAZL, DPPA3, UTF1 and GFRα1 | PGCLCs, and pre-meiotic germ cells | Epigenetic transition from 5-mc to 5-hmc | |||
| Xeno- transplantation | |||||||||
| Dermal fibroblasts from azoospermic and fertile men | BMP4, BMP8, RA, LIF Xeno-transplantation | VASA:GFP reporter | VASA:GFP+ | VASA, PRDM1, PRDM14, DAZL, STELLA, IFITM3, and NANOS3 | VASA, DAZL, STELLA, PLZF, UTF1 and DAZ | PGCLCs, and gonocyte-like cells | Global DNA demethylation | ||
| Somatic cells from a fragile X male patient and normal female | BMP2 or BMP4, LIF, SCF, EGF, and ROCK inhibitor | NANOS3- mCherry reporter | NANOS3+/TNAP+ | NANOS3, BLIMP1, TFAP2C, SOX17, STELLA, OCT4, and PRDM14 | PGCLCs | ||||
| BMP4, ActA, bFGF, LIF | TRA-1–81+/cKIT+ | BLIMP1, STELLA, cKIT, STELLA, NANOS3, and TEX13B | BLIMP1 and STELLA | PGCLCs | Global progress of epigenetic reprogramming | ||||
| Dermal fibroblasts and PMBCs | Activin A, CHIR99021, BMP4, SCF, EGF, LIF | BLIMP1-2 A -tdTomato and TFAP2C-2 A -EGFP reporters | BLIMP1+/TFAP2C+ and EpCAM+/INTEGRINα6+ | BLIMP1, TFAP2C, NANOS3, DPPA3, DDX4, and DAZL | BLIMP1, TFAP2C and SOX17 | PGCLCs | Avoiding of somatic program and epigenetic reprogramming | ||
Figure 1Derivation and application of patient-specific induced pluripotent stem cells (iPSCs) in male infertility. Different types of somatic cells derived from patients with idiopathic infertility are reprogrammed into iPSCs and then differentiated into male germ cells by multiple methods. If necessary, iPSCs with known genetic defects may be corrected by genome editing technology. These cells can be used for in vitro disease modeling, regeneration research and cell-based therapy. In disease modeling, comparison between patients- and normal derived cells potentially provides novel clues to the underlying mechanisms for idiopathic male infertility, which may further lead to the development of therapeutic strategies. PBMCs, peripheral blood mononuclear cells; SSC, spermatogonial stem cell; PGCLCs, human primordial germ cells-like cells.